What is known and objective: Enzalutamide is an androgen receptor inhibitor approved for treatment of metastatic castration-resistant prostate cancer. Enzalutamide is highly protein bound and eliminated primarily by hepatic metabolism; therefore, it is important to understand whether enzalutamide pharmacokinetics is altered by hepatic impairment. Methods: Pharmacokinetic data were obtained from two nonrandomized, open-label, single-dose, phase 1 studies conducted in patients with mild (Child-Pugh class A, n = 6) or moderate (Child-Pugh class B, n = 8) hepatic impairment (NCT01901133) or severe (Child-Pugh class C, n = 8) hepatic impairment (NCT02138162) and their corresponding matched healthy controls; data from both studies are presented here. Subjects with hepatic impairment had liver cirrhosis (n = 19) or chronic hepatitis (n = 3). All subjects received a single oral dose of 160 mg enzalutamide under fasting conditions, with blood samples collected predose and up to 49 days post-dose. Results and discussion: Exposure to enzalutamide active moieties, based on the area under the curve of the sum of enzalutamide and N-desmethyl enzalutamide (an active metabolite with similar potency to enzalutamide), increased by 13%, 18% and 4% in subjects with mild, moderate and severe hepatic impairment, respectively, relative to matched controls. Compared with healthy controls, the mean maximum plasma concentration for enzalutamide active moieties was 24% higher in subjects with mild hepatic impairment and 11% and 41% lower in subjects with moderate and severe hepatic impairment, respectively. Enzalutamide was generally well tolerated, with no clinically significant trends in abnormal laboratory findings, vital signs or electrocardiograms. What is new and conclusions: No major differences in singledose pharmacokinetics were observed in subjects with hepatic impairment vs. matched healthy controls. Therefore, these studies indicate that no initial dose adjustment is necessary when administering enzalutamide to patients with hepatic impairment.
1
Enzalutamide is indicated for treatment of metastatic castrationresistant prostate cancer (mCRPC) in prechemotherapy and post-chemotherapy settings.
2, 3 Clinical efficacy and safety of enzalutamide was established in two randomized, placebocontrolled, multicentre, phase 3 studies: AFFIRM (post-chemotherapy setting) 4 and PREVAIL (chemotherapy-na€ ıve) setting. 5 Single-dose pharmacokinetic studies in healthy male subjects and men with mCRPC have shown that enzalutamide is rapidly absorbed, with a median time to maximum plasma concentration (t max ) of 1Á75 and 1Á0 h, respectively, and a mean terminal half-life (t 1/2 ) of 2Á9 and 5Á8 days, respectively. 6 Steady state is achieved within 28 days, with time-linear pharmacokinetics and minimal fluctuations in plasma concentrations demonstrated thereafter. 6 Enzalutamide is primarily eliminated by hepatic metabolism. 6 The major metabolites are the carboxylic acid metabolite (M1, inactive with respect to mCRPC) and N-desmethyl enzalutamide (M2). M2 is an active metabolite of similar potency to enzalutamide and is thought to contribute to the pharmacologic effects. At steady state, M2 circulates at approximately the same plasma concentration as enzalutamide. 6 Renal elimination is an insignificant pathway for both enzalutamide and M2. 6 CYP2C8 is primarily responsible for biotransformation of enzalutamide, with CYP3A4 playing a minor role. 7 Enzalutamide, M1 and M2 are highly bound to plasma proteins, mainly albumin.
Hepatic impairment function may reduce clearance of drugs metabolized by the liver and may also alter drug distribution due to ascites/fluid retention and/or changes in plasma protein binding of drugs and/or their metabolites. 8 Consequently, the dosage of drugs in patients with impaired hepatic function may need to be reduced.
mCRPC is a disease of older males, 9 and ageing is associated with decreases in liver volume, blood flow, regenerative capacity 10 and drug metabolism. Some liver diseases are also more prevalent with ageing. 10 Given the extent of hepatic metabolism of enzalutamide and the high degree of plasma protein binding of both enzalutamide and its active metabolite, it is important to characterize the pharmacokinetics of enzalutamide in the presence of hepatic impairment. Two non-randomized, open-label, singledose, phase 1 studies in male subjects with different degrees of hepatic impairment (but without prostate cancer) and matched healthy male subjects were performed to assess the impact of hepatic impairment on pharmacokinetics of enzalutamide and its major metabolites and on safety. The dose in these studies, 160 mg, is the marketed dose.
2, 3 Here, we present combined results from both studies, which consist of data for subjects with mild or moderate hepatic impairment from one study and data for subjects with severe hepatic impairment in the other study, including data for the corresponding healthy matched controls from both studies. The effects of mild or moderate hepatic impairment have been reported briefly elsewhere. 6 In the present report, we describe the study in subjects with severe hepatic impairment in addition to providing greater detail on the study in subjects with mild to moderate hepatic impairment to give a complete picture of the pharmacokinetics of enzalutamide across the spectrum of hepatic impairment and to evaluate more comprehensively if dose adjustments are required.
METHODS
Two separate studies of similar design were conducted in accordance with the European Medicines Agency and United States Food and Drug Administration regulatory guidelines on the evaluation of pharmacokinetics in subjects with impaired hepatic function. 11, 12 These studies were non-randomized, open-label, single-dose, phase 1 studies in male subjects who did not have prostate cancer and had varying degrees of hepatic impairment and in healthy matched controls. The first study (NCT01901133) enrolled subjects with mild or moderate hepatic impairment and healthy subjects from a single site in Moldova between October 2011 and January 2012. The National Ethics Committee Clinical Research of Medicines and New Methods of Treatment (Moldova) approved the study protocol. The other study (NCT02138162) enrolled subjects with severe hepatic impairment and healthy subjects at a single centre in Sofia, Bulgaria, between July 2013 and March 2014. The study protocol was approved by the Ethics Committee, University MHAT, Sv. Ivan Rilski, Ltd. Written informed consent was obtained from all subjects before study entry. Both studies were conducted in accordance with the Declaration of Helsinki and the principles of good clinical practice.
Subjects
Men aged 18-69 years inclusive, with a body mass index (BMI) between 18Á5 and 34Á0 kg/m 2 , who were non-fertile or were using (and planned to continue using) highly effective contraception were eligible. Subjects with hepatic impairment (19 with liver cirrhosis, three with chronic hepatitis) and Child-Pugh 13 class A (mild, 5-6 points), class B (moderate, 7-9 points) or class C (severe, 10-15 points) were matched with healthy controls based on BMI (AE15%) and age (AE5 years). Matched controls: in good health as determined by past medical history -vital signs, physical examination, 12-lead electrocardiogram (ECG) and laboratory tests at screening (up to 21 days before study dosing); no significant history of liver disease; negative for HBsAg, anti-HAV, anti-HCV, anti-HIV-1 and anti-HIV-2; and normal renal and hepatic function. Use of prescribed or non-prescribed drugs in the 2 weeks prior to Subjects with mild and moderate hepatic impairment and healthy matched controls were enrolled in the clinical trial NCT01901133. b Two healthy control subjects were incorrectly matched to the subjects with mild hepatic impairment. Therefore, only six subject pairs were available to evaluate the effects of mild hepatic impairment on the pharmacokinetics of enzalutamide.
enzalutamide administration was not permitted, except for occasional paracetamol use. Assessments for renal and hepatic function and key exclusion criteria are listed in Supporting Information (Data S1).
Treatment
Subjects were admitted to the clinic the day before dosing for assessment and remained there until the morning of day 6. On the morning of day 1, each subject received a single oral dose of 160 mg enzalutamide, as four 40 mg capsules, under fasted conditions (at least 10-h overnight). The drug was taken with 240 mL of water. The enzalutamide dose and drug product presentation were the same as the commercial product. Dosing took place under supervision of the investigator site personnel. No food intake was allowed for 4 h after dosing. For the subjects with hepatic impairment, doses of other required medication had to remain stable during the studies. Subjects who required any disallowed medications during the study were withdrawn. Healthy controls who required use of any medication, other than occasional paracetamol, were also withdrawn.
Sample collection
Details of sample collection are provided in Supporting Information (Data S1).
Pharmacokinetic analysis
Measurement of enzalutamide and metabolite concentrations in plasma and plasma dialysate was performed by PharmaNet USA (Princeton, NJ, USA) [mild to moderate impairment study] or inVentiv Health Clinical (Princeton, NJ, USA) [severe impairment study], using a validated liquid chromatography-tandem mass spectrometry method.
14 Details are provided in Supporting Information (Data S1).
Safety assessments
Treatment-emergent adverse events (AEs), vital signs, 12-lead ECGs, physical examinations and clinical laboratory tests were assessed throughout the study, with a final safety follow-up visit 7-10 days after the last blood sample was taken for pharmacokinetic analysis. All observed or spontaneously reported AEs were documented, and severity was assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.03. 15 The Child-Pugh classification was assessed prestudy on day 26 and at the final safety follow-up visit.
Statistical analysis
All subjects who received enzalutamide were included in the safety population. All subjects from the safety population for (d)
Matched controls (mild), n = 6
Moderate, n = 8
Matched controls (moderate), n = 8
Severe, n = 8
Matched controls (severe), n = 8 whom sufficient plasma concentration data were available to derive at least one pharmacokinetic parameter and for whom the time of dosing was known were included in the pharmacokinetic population. Further details of statistical analysis are provided in Supporting Information (Data S1).
RESULTS

Demographic characteristics
Forty-nine subjects enrolled in these studies, with 48 subjects completing follow-up (24 subjects with hepatic impairment [mild, eight; moderate, eight; severe, eight] and 24 healthy controls). Two control subjects were incorrectly matched to the subjects with mild hepatic impairment. Therefore, only six subject pairs were available to evaluate the effects of mild hepatic impairment on the pharmacokinetics of enzalutamide. Demographic and baseline characteristics of all subjects are summarized in Table 1 . Across the two studies, subjects' ages ranged from 24 to 67 years and BMIs ranged from 23Á1 to 33Á8 kg/m 2 . All subjects with mild and severe hepatic impairment had liver cirrhosis. Of the subjects with moderate hepatic impairment, five had cirrhosis and three had chronic hepatitis.
Pharmacokinetics of enzalutamide and its metabolites
Mean plasma concentration-time profiles of enzalutamide, M2 and the sum of enzalutamide plus M2 in subjects with hepatic impairment and matched controls are shown in Fig. 1 .
Pharmacokinetic parameters for enzalutamide, M2 and the sum of enzalutamide plus M2 are summarized in Table 2 , and the statistical comparisons for area under the plasma concentration vs. time curve from time 0 to infinity (AUC 0-inf ) and maximum plasma concentration (C max ) for enzalutamide, M2 and the sum of enzalutamide plus M2 (both total and unbound) are summarized in Table 3 and shown in Fig. 2 .
Compared with healthy controls, enzalutamide mean C max was 24% higher in the group with mild hepatic impairment and 11% and 41% lower in the groups with moderate and severe hepatic impairment, respectively (Table 3) . Enzalutamide AUC 0-inf values in subjects with mild and severe hepatic impairment were similar to those of controls and 29% higher in subjects with moderate hepatic impairment (Table 3) .
Median enzalutamide t max in subjects with mild or moderate hepatic impairment was 0Á75 and 1 h, respectively, comparable with the values in controls (Table 2) . Median enzalutamide t max in subjects with severe hepatic impairment and in control subjects was 1 and 1Á5 h, respectively (Table 2) . 
Mean t 1/2 for enzalutamide was shorter in subjects with mild hepatic impairment than in controls (Table 2 ). In subjects with moderate hepatic impairment, mean t 1/2 was approximately 80% longer (Table 2) ; this difference was highly influenced by a single subject, with a t 1/2 of 597Á2 h. When median t 1/2 values for subjects with moderate and normal hepatic function were calculated, there was only a small difference between the groups (112Á4 vs. 94Á2 h, respectively). Mean t 1/2 in subjects with severe hepatic impairment was approximately 120% longer than in the controls (Table 2) . This difference was related to the difference in apparent volume of distribution (V z /F) [154Á4 vs. 83Á5 L], whereas the apparent clearance (CL/F) showed minimal difference between the two groups (0Á59 vs. 0Á53 L/h) ( Table 2) .
As albumin concentrations tend to decline if hepatic impairment is present, V z /F of enzalutamide was compared with baseline albumin concentrations. Mean baseline albumin concentrations were lower in subjects with severe hepatic impairment compared with control subjects -28Á5 g/L (range, 20-35 g/L) vs. 43Á5 g/L (range, 41-47 g/L), respectively. V z /F seemed to be higher in those subjects with low albumin concentrations (Fig. 3) . Albumin concentrations had no effect on CL/F (data not shown). Summarized data from both studies (Fig. 3) revealed only a moderate effect of albumin levels on the V z /F of enzalutamide (R 2 = 0Á0674). For the sum of enzalutamide plus M2, C max differences were similar to those for enzalutamide in all groups, and differences between subjects with hepatic impairment and matched subjects were also comparable to those for enzalutamide alone for all three groups (Table 3) . AUC 0-inf values were 13%, 18% and 4% higher in subjects with mild, moderate and severe hepatic impairment, respectively, compared with controls (Table 3) .
Mean t 1/2 for M2 was longer than for enzalutamide in all groups and longer in subjects with moderate and severe hepatic impairment compared with their controls (Table 2 ). Mean t 1/2 for the sum of enzalutamide plus M2 followed similar trends to values for enzalutamide and M2 alone ( Table 2) .
Details of unbound pharmacokinetics are provided in Supporting Information (Data S1).
Safety
Three subjects across the two studies each experienced one AE, two of which were deemed treatment emergent. One subject with moderate hepatic impairment experienced gynecomastia (NCI-CTCAE grade 1), which was considered possibly related to the study drug by the investigator; this event resolved and the subject completed the study. One control subject experienced a serious AE of hypertensive crisis (NCI-CTCAE grade 2) that was considered possibly related to the study drug on day 1 after completing dosing. This event resolved the same day, but the subject withdrew from the study after the 36 h post-dose blood sample was collected. The third AE, a single episode of syncope, occurred predose in another control subject. The subject collapsed during cannula insertion but recovered, and the subject continued in the study.
No clinically significant or study drug-related trends in abnormal laboratory safety findings, vital signs or ECGs were observed. No subjects died in either study.
DISCUSSION
The results of these two studies demonstrate that hepatic impairment does not have a clinically meaningful effect on the The table presents study specific data (i.e. the results of the two studies were not pooled and reanalysed). AUC 0-inf, area under the plasma concentration vs. time curve from time 0 to infinity; AUC 0-inf,u , area under the plasma concentration vs. time curve from time 0 to infinity for unbound enzalutamide, M2 or the sum of enzalutamide plus M2; C max , maximum plasma concentration; C max,u , maximum unbound plasma concentrations; M2, N-desmethyl enzalutamide.
pharmacokinetics and safety of enzalutamide and, therefore, has no impact on dosing. Exposure to enzalutamide active moieties (i.e. enzalutamide plus M2), based on the AUC 0-inf , was comparable in subjects with severe hepatic impairment and matched healthy controls. In subjects with mild or moderate hepatic impairment, exposure to enzalutamide plus M2 was only slightly higher than in the control subjects and was not clinically meaningful. Furthermore, the information that is available on the pharmacokinetics of enzalutamide in patients with prostate cancer does not suggest any major differences with healthy subjects; therefore, we believe that the hepatic impairment studies provide a useful estimate of the expected effects of hepatic impairment in patients with prostate cancer. With regard to classification, although the NCI criteria may give a better assessment in cancer patients, the patients with hepatic impairment/cirrhosis who participated in these two studies did not suffer from prostate cancer or any other form of cancer. For this reason, the Child-Pugh classification was used. Only one patient in the group with mild and one patient in the group with moderate hepatic impairment showed a mild (i.e. >1Á0-1Á5 times upper limit of normal [ULN]) elevation of total bilirubin; while in the group with severely impaired patients, four showed a moderate elevation (i.e. >1Á5-3 times ULN) in bilirubin, three showed a severe elevation (i.e. >3 times ULN), and one showed no elevation. Consequently, classification based on bilirubin alone would give similar results as Child-Pugh.
Enzalutamide is highly protein bound, has a long t 1/2 (5Á8 days in patients) and is almost exclusively eliminated by hepatic metabolism, with a major metabolite (M2) having similar potency to enzalutamide. 6 It was anticipated that hepatic impairment might change the exposure to enzalutamide and/or its metabolites, which could necessitate enzalutamide dosage adjustments.
The observed changes in the AUC 0-inf and AUC 0-inf,u of the sum of enzalutamide plus M2 in subjects with hepatic impairment were small. Mean CL/F was similar in control subjects and subjects with severe hepatic impairment. However, mean V z /F increased 1Á83-fold (about 154 and 84 L for subjects with severe hepatic impairment and for control subjects, respectively). The longer t 1/2 in subjects with severe hepatic impairment can be explained by the increased V z /F, using the following relationship: t 1/2 = 0Á693 (V z / F)/(CL/F). Assuming CL/F is unchanged, a 1Á83-fold increase in V z / F in subjects with severe hepatic impairment will result in an 83% longer half-life, which is close to the observed 120% increase compared with the matched control subjects. As a consequence, time Mean change relative to matched controls (%) Fig. 2 . Forest plot summarizing the effects of hepatic impairment (mild, moderate and severe) on exposure to total and to unbound enzalutamide and the sum of enzalutamide plus M2 (AUC 0-inf , C max , AUC 0-inf,u and C max,u ). AUC 0-inf, area under the plasma concentration vs. time curve from time 0 to infinity; AUC 0-inf,u , area under the plasma concentration vs. time curve from time 0 to infinity for unbound enzalutamide, M2 or the sum of enzalutamide plus M2; CI, confidence interval; C max , maximum plasma concentration; C max,u , maximum unbound plasma concentrations; M2, N-desmethyl enzalutamide; PK, pharmacokinetic.
to steady state will increase proportionately if patients have severe hepatic impairment. Increases in the V z /F of a drug in subjects with hepatic impairment may be related to the presence of ascites/fluid retention and/or changes in plasma protein binding. Although lower albumin concentrations in subjects with hepatic impairment can alter plasma protein binding, the enzalutamide f u in our subjects with mild or moderate hepatic impairment was broadly comparable with that of the control subjects. In contrast, severe hepatic impairment resulted in a change in plasma protein binding, with the mean f u 30% higher than that seen in the control subjects. In agreement with the higher f u values, V z /F of enzalutamide was higher in subjects with low baseline albumin concentrations; there was no effect of albumin concentrations on the unbound V z /F of enzalutamide. Summarizing the data across the two studies suggested only a moderate effect of albumin concentrations on the V z /F of enzalutamide. The healthy controls matched to subjects with severe hepatic impairment had the highest albumin concentrations, even though they had comparable demographics to the controls for the subjects with mild and moderate hepatic impairment. It was also apparent that V z /F values for the subjects with severe hepatic impairment overlapped with the values for the healthy control groups. It seems that the effect on V z /F in the severe hepatic impairment study is mainly driven by the relatively high albumin concentrations for the matched control group (43Á5 g/L [range, 41-47 g/L]), whereas the albumin concentrations for the subjects with severe hepatic impairment are low (28Á5 g/L [range, 20-35 g/L]), as expected. In the severe hepatic impairment group, the 30% increase in f u of enzalutamide may be insufficient to explain the change in V z /F. Therefore, the increase in V z /F is most likely related to both presence of ascites and lower albumin concentrations.
There is a hypothesis for why the exposure to enzalutamide, which is extensively metabolized, is only to a small extent affected by hepatic impairment. Enzalutamide is metabolized to M2 via the intermediate metabolite M6. 16, 17 The metabolism to M6 depends on CYP2C8 and, to a lesser extent, on CYP3A4. 16, 17 The subsequent step to M2 is non-enzymatic. Hepatic impairment has been described to reduce metabolic activity of the liver, especially in subjects with severe hepatic impairment, so it is likely that intrinsic clearance of enzalutamide was decreased. However, due to the decrease in plasma albumin, the free fraction of enzalutamide was increased. A higher free fraction will facilitate metabolism. Apparently, the increase in free fraction was sufficient to compensate for the decrease in intrinsic clearance. A higher free fraction will increase the volume of distribution, which explains why the t 1/2 increased and the C max decreased whereas the AUC was relatively unaltered.
WHAT IS NEW AND CONCLUSIONS
Based on pharmacokinetic and safety findings from these two studies, a single 160 mg oral dose of enzalutamide was generally safe and well tolerated in subjects with mild, moderate or severe hepatic impairment and in their respective matched healthy controls with normal hepatic function. The metabolism of enzalutamide seems to be relatively insensitive to hepatic impairment, and no initial dose adjustment is necessary when enzalutamide is used to treat patients with mCRPC and hepatic impairment of any degree.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article:
Data S1 Supplementary materials. 
